These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 18845089)

  • 21. Medication formulation affects quality of life: a randomized single-blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis.
    Bergstrom KG; Arambula K; Kimball AB
    Cutis; 2003 Nov; 72(5):407-11. PubMed ID: 14655784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An open-label study of an herbal topical medication (QoolSkin) for patients with chronic plaque psoriasis.
    Cohen AD; Shalev R; Yaniv R; Shemer A
    ScientificWorldJournal; 2007 Jul; 7():1063-9. PubMed ID: 17619788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term efficacy and safety of infliximab maintenance therapy in patients with plaque-type psoriasis in real-world practice.
    Shear NH; Hartmann M; Toledo-Bahena M; Katsambas A; Connors L; Chang Q; Yao R; Nograles K; Popmihajlov Z;
    Br J Dermatol; 2014 Sep; 171(3):631-41. PubMed ID: 24673357
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
    Papp KA; Langley RG; Sigurgeirsson B; Abe M; Baker DR; Konno P; Haemmerle S; Thurston HJ; Papavassilis C; Richards HB
    Br J Dermatol; 2013 Feb; 168(2):412-21. PubMed ID: 23106107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergism between narrowband ultraviolet B phototherapy and etanercept for the treatment of plaque-type psoriasis.
    Calzavara-Pinton PG; Sala R; Arisi M; Rossi MT; Venturini M; Ortel B
    Br J Dermatol; 2013 Jul; 169(1):130-6. PubMed ID: 23834117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of clinical effects of psoriasis treatment regimens among calcipotriol alone, narrowband ultraviolet B phototherapy alone, combination of calcipotriol and narrowband ultraviolet B phototherapy once a week, and combination of calcipotriol and narrowband ultraviolet B phototherapy more than twice a week.
    Takahashi H; Tsuji H; Ishida-Yamamoto A; Iizuka H
    J Dermatol; 2013 Jun; 40(6):424-7. PubMed ID: 23414298
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment.
    Papp K; Leonardi C; Menter A; Thompson EH; Milmont CE; Kricorian G; Nirula A; Klekotka P
    J Am Acad Dermatol; 2014 Dec; 71(6):1183-1190.e3. PubMed ID: 25313095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Calcipotriol ointment versus cream in psoriasis vulgaris.
    Duweb G; Aldebani S; Elzorghany A; Benghazil M; Alhaddar J
    Int J Clin Pharmacol Res; 2003; 23(2-3):47-51. PubMed ID: 15018018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
    Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
    Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Atorvastatin for the treatment of plaque-type psoriasis.
    Faghihi T; Radfar M; Mehrabian Z; Ehsani AH; Rezaei Hemami M
    Pharmacotherapy; 2011 Nov; 31(11):1045-50. PubMed ID: 22026392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment of plaque-type psoriasis with cream-PUVA therapy].
    Steinmeyer K; Grundmann-Kollmann M; Podda M; Kaufmann R
    Hautarzt; 2001 Oct; 52(10):885-7. PubMed ID: 17690819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fumaderm® in daily practice for psoriasis: dosing, efficacy and quality of life.
    Walker F; Adamczyk A; Kellerer C; Belge K; Brück J; Berner T; Merten K; Núnez Gómez N; Neureither M; Röcken M; Ghoreschi K;
    Br J Dermatol; 2014 Nov; 171(5):1197-205. PubMed ID: 24813676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of three methods for measuring psoriasis severity in clinical studies (Part 1 of 2): change during therapy in Psoriasis Area and Severity Index, Static Physician's Global Assessment and Lattice System Physician's Global Assessment.
    Chow C; Simpson MJ; Luger TA; Chubb H; Ellis CN
    J Eur Acad Dermatol Venereol; 2015 Jul; 29(7):1406-14. PubMed ID: 25917315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study.
    Thaçi D; Ortonne JP; Chimenti S; Ghislain PD; Arenberger P; Kragballe K; Saurat JH; Khemis A; Sprøgel P; Esslinger HU; Unnebrink K; Kupper H
    Br J Dermatol; 2010 Aug; 163(2):402-11. PubMed ID: 20377585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis.
    D'Souza LS; Payette MJ
    J Am Acad Dermatol; 2015 Apr; 72(4):589-98. PubMed ID: 25631851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative efficacy of biologics in psoriasis: a review.
    Kim IH; West CE; Kwatra SG; Feldman SR; O'Neill JL
    Am J Clin Dermatol; 2012 Dec; 13(6):365-74. PubMed ID: 22967166
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis.
    Zhu B; Edson-Heredia E; Cameron GS; Shen W; Erickson J; Shrom D; Wang P; Banerjee S; Gordon KB
    Br J Dermatol; 2013 Dec; 169(6):1337-41. PubMed ID: 24032554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
    Al-Mutairi N; Nour T
    Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Topical therapy for psoriasis with the use of augmented betamethasone and calcipotriene on alternate weeks.
    Singh S; Reddy DC; Pandey SS
    J Am Acad Dermatol; 2000 Jul; 43(1 Pt 1):61-5. PubMed ID: 10863225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.